8:00 – 8:05 Welcome & Introductions: Mitchell Krucoff, MD (Duke)

8:05 – 8:55 Session 1: Cardiogenic Shock in 2020 and Beyond.
- Overview of Shock 1 and Shock 2: Marc Samsky MD (Duke) (10 min)
- FDA Perspectives: Priorities for 2020 Bram Zuckerman (10 min)
- AHA Shock initiative: Mariell Jessup, MD (10 min)
- Dealing with Safety in High Risk Populaitons: Insights from DES/PAD. Mitchell Krucoff, MD (Duke) (10 min)

8:55 – 10:00 Session 2: Shock Research Network. How can we rapidly identify and triage patients with shock?
- Are shock teams and networks necessary? What are the priorities and minimum requirements for a “Shock Team/Network?” Navin Kapur, MD (Tufts) (5 min)
- An ELSO view Ryan Barbaro, MD (University of Michigan) (5 min)
- Industry: Is Shock Network Research attractive? Zhen Zhang, MD (Abbott) (5 min)
- NIH Perspective George Sopko, MD (5 min)

Moderated Discussion (45 min): Lead Discussants: Nader Moazami, MD (New York University); Seth Bilazarian, MD (Abiomed)

10:00-10:10: Break

- Informed consent solutions for shock trials of devices: FDA view John Sapirstein, MD (FDA) (5 min)
- What strategies are used in Europe? Alastair Proudfoot, MD (St Bartholomew’s Hospital) (5 min)

Moderated Discussion (45 min): Lead Discussants: Jason Katz, MD (Duke)

11:15 – 12:30 Session 4: Are current shock definitions adequate? What core data do we need?
Moderators: Ron Waksman, MD (MedStar) and Ileana Pina, MD (FDA)
- Adopting Key Variables from SCAI definitions: Timothy Henry, MD (Christ Hospital) (5 min)
- Key predictive model variables often missed in clinical practice: William O’Neill, MD (Henry Ford) (5 min)
- Updates on Shock-ARC: William Abraham, MD (Ohio State) (5 min)
- NIH Perspective Patrice Desvigne-Nickens, MD (5 min)

Moderated Discussion (40 min): Lead Discussants: Ernest Spitzer, MD (Cardialysis)

12:30-13:15: Lunch

13:15-14:35 Session 5: Shock Priority Clinical Trials
Moderators: Sunil Rao, MD (Duke) and Fernando Aguel, MS (FDA)
- The intensivist perspective: Trial priorities for MCS in the CICU? David Morrow, MD (Harvard) (5 min)
- The interventionalist perspective: STEMI-Shock: What would the first randomized question be? Holger Thiele, MD (University of Leipzig)(5 min)
- The HF perspective: Where do inotropes fit in? Nasrien Ibrahim, MD (Mass General Hospital) (5 min)
- Percutaneous vs. ECMO trials: do we need different centers? Jacob Schroder, MD (Duke) (5 min)
- PCI VS CABG- Nathaniel Smilowitz, MD (New York University) (5 min)
- INTERMACS: Success Story or Lessons Learned? Mandatory registry participation. Patrice Desvigne-Nickens, MD (NIH)(5 min)
- Industry Perspective: Seth Bilazarian, MD (Abiomed) (5 min)

Moderated Discussion (45 min): Lead Discussants Andrew Althouse, PhD (Pitt); Eric Chen, MS (Abbott)
14:30 – 16:00 Session 7: Next Steps to Advancing Pragmatic Priorities & Pathways in Shock Research

Moderator: Mitchell Krucoff, MD (Duke), Bram Zuckerman, MD (FDA)

Summaries from the Day (no slides):
- Shock research centers network: William O’Neill, MD (Henry Ford) (5 min)
- Shock nomenclature & definitions: Ron Waksman, MD (MedStar) (5 min)
- Resources for Shock Network Research: Sunil Rao, MD (Duke) (5 min)
- Shock Priority Clinical Trials: Fernando Aguel, MS (FDA) (5 min)
- Trial/Registry/Claims Data: Mauro Moscucci, MD, MBA (FDA)

Moderated Discussion (40 min): Lead Discussants:
William Abraham, MD (Ohio State), Judith Hochman, MD (New York University), Holger Thiele, MD (University of Leipzig)

Closing Comments